VEA
JBIO icon

Virtus ETF Advisers’s Jade Biosciences JBIO Stock Holding History

Virtus ETF Advisers’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-107
Closed -$7.83K – 470
2024
Q3 		$7.83K Buy
107
+2
+2% +$129 ﹤0.01% 454
2024
Q2 		$6.11K Buy
+105
New +$69.6K ﹤0.01% 448

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

Virtus ETF Advisers's JBIO Position: Q4 2024 in Review

Virtus ETF Advisers sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 107 shares — an estimated $7.83K sold.

Virtus ETF Advisers first reported a position in JBIO in Q2 2024 and held it in 2 quarters. The position peaked at $7.83K in Q3 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • Virtus ETF Advisers reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 107 Jade Biosciences shares in Q4 2024, an estimated $7.83K.
  • Virtus ETF Advisers first reported a position in Jade Biosciences in Q2 2024 and held it in 2 quarters.
  • Virtus ETF Advisers's Jade Biosciences position peaked at $7.83K in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.